Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Histopathological Diagnosis in Soft Tissue Sarcoma

November 14th 2017

Heterogeneity of Soft Tissue Sarcomas

November 14th 2017

Efforts Continue to Expand Immunotherapy in CRC

November 13th 2017

Johanna Bendell, MD, discusses the current and emerging treatment landscape of immunotherapy for patients with CRC.

Expert Discusses Treatment Options in Advanced CRC

November 13th 2017

Cathy Eng, MD, discusses optimizing sequencing beyond disease progression in CRC.

Refining Chemo Regimens Among Keys to CRC Advances

November 13th 2017

Hans-Joachim Schmoll, MD, discusses updated CHARTA findings, the current role of chemotherapy in patients with metastatic colorectal cancer (CRC), and his predictions for the future CRC treatment landscape.

Bevacizumab Biosimilar Nears European Approval

November 11th 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of the bevacizumab biosimilar ABP 215 for the treatment of patients across several tumor types.

MSI-H Experience Delivers Another Exciting Breakthrough in Immuno-Oncology

November 10th 2017

Immunotherapy is being positioned as an earlier therapeutic option for patients with high levels of microsatellite instability or mismatch repair deficiency, regardless of their tumor location, expert says.

Dr. Taieb Discusses Sidedness in Metastatic Colon Cancer

November 10th 2017

Julien Taieb, MD, head of the gastroenterology and gastrointestinal oncology department of the Georges Pompidou European Hospital, Paris Descartes University, discusses sidedness in metastatic colon cancer.

Dr. Alberts on Unmet Needs in CRC

November 10th 2017

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses unmet needs facing patients with colorectal cancer (CRC).

Dr. Eng on Roles of Regorafenib and TAS-102 in CRC Treatment

November 10th 2017

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ongoing roles of regorafenib (Stivarga) and TAS-102 (Lonsurf) in colorectal cancer (CRC) treatment.

Dr. Larson on Ongoing Trials in Colorectal Cancer

November 9th 2017

Tim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).

Dr. O'Neil on Left-Sided Versus Right-Sided CRC

November 9th 2017

Bert O'Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses left-sided versus right-sided colorectal cancer (CRC).

Dr. Bekaii-Saab on the Response Rate of Pembrolizumab in MSI-H CRC

November 1st 2017

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the response rate of pembrolizumab (Keytruda) for patients with microsatellite instability-high (MSI-H) colorectal cancer (CRC).

CDK4/6 Inhibitors Explored in KRAS-Mutant Cancers

October 31st 2017

A new generation of more selective inhibitors of CDK4 and CDK6 has entered the clinic in combination therapies for patients with breast cancer. These agents also are being investigated in patients with KRAS-mutant malignancies.

Dr. Schmoll on the Toxicity of the CHARTA Study in CRC

October 10th 2017

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, discusses the toxicity of the CHARTA study for patients with colorectal cancer (CRC).

Expert Discusses Ongoing Advances With Immunotherapy in CRC

September 28th 2017

Tanios Bekaii-Saab, MD, discusses the emerging role of immunotherapy in patients with MSI-H colorectal cancer.

Grothey Highlights Biomarker Research in CRC

September 26th 2017

Axel Grothey, MD, discusses current first-line treatments for patients with CRC and the importance of developing biomarkers for this population.

Therapies in Development to Improve Outcomes in BRAF-Mutated CRC

September 26th 2017

Tim G. Larson, MD, discusses emerging data involving immunotherapy for patients with microsatellite instability (MSI)/microsatellite stable (MSS) colorectal cancer (CRC) and highlighted some of the identified molecular mutations in patients with CRC

Dr. Larson on Immunotherapy for Colorectal Cancer

September 26th 2017

Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Expert Reflects on Recent Trial Results in CRC and Small Bowel Cancer

September 21st 2017

Heinz-Josef Lenz, MD, discusses his study of molecular variations between small bowel adenocarcinomas, right-sided colon cancers, and gastroesophageal cancers.